Appointments at Cadence Pharmaceuticals
This article was originally published in Scrip
Cadence Pharmaceuticals (US) has appointed Dr Todd Rich to the company's board of directors and named Malcolm Lloyd-Smith senior vice-president of regulatory affairs and quality assurance. Mr Lloyd-Smith assumes the role previously held by Malvina Laudicina, who resigned from the company; he was previously vice-president and head of global regulatory affairs at Elan Pharmaceuticals. Dr Rich is vice-president of development regulatory, medical information, drug safety, quality and compliance at Genentech.
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.